BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 23836364)

  • 1. [Postoperative prognosis of chromophobic renal cell carcinoma: comparative analysis of the multinational CORONA database].
    May M; Zigeuner R; Aziz A; Cindolo L; Gilfrich C; Schips L; De Cobelli O; Rocco B; De Nunzio C; Tubaro A; Coman I; Feciche B; Truss M; Hoschke B; Dalpiaz O; Stoltze A; Fenske F; Fritsche HM; Chromecki T; Lebentrau S; Figenshau RS; Madison K; Sánchez-Chapado M; Del Carmen Santiago Martin M; Salzano L; Lotrecchiano G; Joniau S; Waidelich R; Stief CG; Brookman-May S; ;
    Urologe A; 2014 Feb; 53(2):228-35. PubMed ID: 23836364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
    Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
    BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does chromophobe renal cell carcinoma have better survival than clear cell renal cell carcinoma? A clinical-based cohort study and meta-analysis.
    Jiang HM; Wei JH; Zhang ZL; Fang Y; Zhou BF; Chen ZH; Lu J; Liao B; Zhou FJ; Luo JH; Chen W
    Int Urol Nephrol; 2016 Feb; 48(2):191-9. PubMed ID: 26589610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical behavior of chromophobe renal cell carcinoma is less aggressive than that of clear cell renal cell carcinoma, independent of Fuhrman grade or tumor size.
    Steffens S; Roos FC; Janssen M; Becker F; Steinestel J; Abbas M; Steinestel K; Wegener G; Siemer S; Thüroff JW; Hofmann R; Stöckle M; Schrader M; Hartmann A; Junker K; Kuczyk MA; Schrader AJ;
    Virchows Arch; 2014 Oct; 465(4):439-44. PubMed ID: 25178561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do young patients with renal cell carcinoma feature a distinct outcome after surgery? A comparative analysis of patient age based on the multinational CORONA database.
    Aziz A; May M; Zigeuner R; Pichler M; Chromecki T; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Tubaro A; Coman I; Truss M; Dalpiaz O; Hoschke B; Gilfrich C; Feciche B; Fenske F; Sountoulides P; Figenshau RS; Madison K; Sánchez-Chapado M; Del Carmen Santiago Martin M; Wieland WF; Salzano L; Lotrecchiano G; Waidelich R; Stief C; Brookman-May S;
    J Urol; 2014 Feb; 191(2):310-5. PubMed ID: 23973516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).
    Brookman-May S; May M; Shariat SF; Xylinas E; Stief C; Zigeuner R; Chromecki T; Burger M; Wieland WF; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Feciche B; Truss M; Gilfrich C; Pahernik S; Hohenfellner M; Zastrow S; Wirth MP; Novara G; Carini M; Minervini A; Simeone C; Antonelli A; Mirone V; Longo N; Simonato A; Carmignani G; Ficarra V;
    Eur Urol; 2013 Sep; 64(3):472-7. PubMed ID: 22748912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium.
    Abu-Ghanem Y; Powles T; Capitanio U; Beisland C; Järvinen P; Stewart GD; Gudmundsson EO; Lam TB; Marconi L; Fernandéz-Pello S; Nisen H; Meijer RP; Volpe A; Ljungberg B; Klatte T; Dabestani S; Bex A
    Eur Urol Oncol; 2021 Jun; 4(3):473-482. PubMed ID: 33109495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histological subtype of renal cell carcinoma significantly affects survival in the era of partial nephrectomy.
    Nguyen DP; Vertosick EA; Corradi RB; Vilaseca A; Benfante NE; Touijer KA; Sjoberg DD; Russo P
    Urol Oncol; 2016 Jun; 34(6):259.e1-8. PubMed ID: 26947350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gender differences in clinicopathological features and survival in surgically treated patients with renal cell carcinoma: an analysis of the multicenter CORONA database.
    May M; Aziz A; Zigeuner R; Chromecki T; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Tubaro A; Coman I; Truss M; Dalpiaz O; Hoschke B; Gilfrich C; Feciche B; Stoltze A; Fenske F; Fritsche HM; Figenshau RS; Madison K; Sánchez-Chapado M; Martin Mdel C; Salzano L; Lotrecchiano G; Joniau S; Waidelich R; Stief C; Brookman-May S;
    World J Urol; 2013 Oct; 31(5):1073-80. PubMed ID: 23568445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The natural history of renal cell carcinoma with isolated lymph node metastases following surgical resection from 2006 to 2013.
    Golijanin B; Pereira J; Mueller-Leonhard C; Golijanin D; Amin A; Mega A; Boorjian SA; Thompson RH; Leibovich BC; Gershman B
    Urol Oncol; 2019 Dec; 37(12):932-940. PubMed ID: 31570248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery.
    Leibovich BC; Lohse CM; Cheville JC; Zaid HB; Boorjian SA; Frank I; Thompson RH; Parker WP
    Eur Urol; 2018 May; 73(5):772-780. PubMed ID: 29398265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromophobe Renal Cell Carcinoma: Results From a Large Single-Institution Series.
    Casuscelli J; Becerra MF; Seier K; Manley BJ; Benfante N; Redzematovic A; Stief CG; Hsieh JJ; Tickoo SK; Reuter VE; Coleman JA; Russo P; Ostrovnaya I; Hakimi AA
    Clin Genitourin Cancer; 2019 Oct; 17(5):373-379.e4. PubMed ID: 31326335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic features of pathologic stage T1 renal cell carcinoma after radical nephrectomy.
    Lau WK; Cheville JC; Blute ML; Weaver AL; Zincke H
    Urology; 2002 Apr; 59(4):532-7. PubMed ID: 11927308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma.
    Beck SD; Patel MI; Snyder ME; Kattan MW; Motzer RJ; Reuter VE; Russo P
    Ann Surg Oncol; 2004 Jan; 11(1):71-7. PubMed ID: 14699037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local ablation vs partial nephrectomy in T1N0M0 renal cell carcinoma: An inverse probability of treatment weighting analysis.
    Shi L; He Y; Liu C; Qian X; Wang Z
    Cancer Med; 2020 Nov; 9(21):7988-8003. PubMed ID: 32888392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic implications of sarcomatoid and rhabdoid differentiation in patients with grade 4 renal cell carcinoma.
    Kara O; Maurice MJ; Zargar H; Malkoc E; Akca O; Andrade HS; Ramirez D; Caputo PA; Nelson RJ; Rini B; Kaouk JH
    Int Urol Nephrol; 2016 Aug; 48(8):1253-1260. PubMed ID: 27215555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of clinical and histopathological parameters on disease specific survival in patients with collecting duct renal cell carcinoma: development of a disease specific risk model.
    May M; Ficarra V; Shariat SF; Zigeuner R; Chromecki T; Cindolo L; Burger M; Gunia S; Feciche B; Wenzl V; Aziz A; Chun F; Becker A; Pahernik S; Simeone C; Longo N; Zucchi A; Antonelli A; Mirone V; Stief C; Novara G; Brookman-May S; ;
    J Urol; 2013 Aug; 190(2):458-63. PubMed ID: 23434943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nephron-sparing surgery for renal cell carcinoma: clinicopathologic features predictive of patient outcome.
    Krejci KG; Blute ML; Cheville JC; Sebo TJ; Lohse CM; Zincke H
    Urology; 2003 Oct; 62(4):641-6. PubMed ID: 14550434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality Within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma.
    Morgan TM; Mehra R; Tiemeny P; Wolf JS; Wu S; Sangale Z; Brawer M; Stone S; Wu CL; Feldman AS
    Eur Urol; 2018 May; 73(5):763-769. PubMed ID: 29249291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.
    Leibovich BC; Cheville JC; Lohse CM; Zincke H; Frank I; Kwon ED; Merchan JR; Blute ML
    J Urol; 2005 Nov; 174(5):1759-63; discussion 1763. PubMed ID: 16217278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.